The results of HPS-2 seem to validate the wisdom of the initial FDA decision.

FORBES: Lessons From Merck's Niacin Failure

He said that it was too early to make comments based on comparisons between the studies, and that there were still many unanswered questions about the study Oxford conducted for Merck, known as HPS-2 Thrive.

FORBES: Is This The End Of A Widely Used Heart Drug?